Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed breast cancer~  * Locally advanced or metastatic disease~ * Disease progression after at least 1 prior chemotherapy regimen for metastatic disease~    * No more than 2 prior chemotherapy regimens for metastatic disease (prior neoadjuvant or adjuvant treatment will not be included in determining the number of prior chemotherapy regimens)~* Measurable disease~* No known symptomatic or untreated brain metastases or carcinomatous meningitis~  * Previously treated and clinically stable brain metastases allowed provided patient has been off steroids for \> 7 days~* Hormone receptor status not specified~PATIENT CHARACTERISTICS:~* Male or female~* Menopausal status not specified~* ECOG performance status 0-2~* Life expectancy ≥ 3 months~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Bilirubin ≤ 1.5 times upper limit of normal (ULN)~* AST or ALT ≤ 2.5 times ULN~* Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 60 mL/min~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 3 months after completion of study therapy~* Able to swallow oral medication~* No coexisting medical condition that would preclude study compliance~* No uncontrolled illness, including any of the following:~  * Symptomatic congestive heart failure~ * Unstable angina pectoris~ * Cardiac arrhythmia requiring therapy~ * Myocardial infarction within the past 6 months~ * Active infection~* No New York Heart Association class III-IV cardiac disease~* No history of allergic reaction attributed to compounds of similar chemical or biologic composition to gemcitabine hydrochloride and/or imatinib mesylate~* No other primary malignancies within the past 5 years except for carcinoma in situ of the cervix or nonmelanoma skin cancer~* No known chronic liver disease (i.e., chronic active hepatitis or cirrhosis)~* No known HIV infection~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Recovered from all prior therapy~* More than 2 weeks since prior surgery~* At least 2 weeks since prior hormonal therapy~* At least 2 weeks since prior trastuzumab (Herceptin®)~* At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas)~* At least 3 weeks since prior anti-vascular endothelial growth factor therapy~* More than 28 days since prior investigational agents~* At least 3 weeks since prior radiotherapy~  * Must have evidence of ≥ 1 measurable target lesion outside the irradiated fields OR radiologically confirmed disease progression within the irradiated fields after completion of radiotherapy~* No prior imatinib mesylate for metastatic disease~* No prior gemcitabine hydrochloride for metastatic disease~* More than 6 months since prior adjuvant gemcitabine hydrochloride~* No other concurrent investigational or commercial agents~* No concurrent therapeutic anticoagulation with warfarin (e.g., Coumadin® or Coumadine®)~  * Concurrent heparin or low-molecular weight heparin (e.g., Lovenox®) for therapeutic anticoagulation allowed~ * Concurrent prophylactic warfarin therapy (e.g., mini-dose Coumadin® ≤ 1 mg daily) to maintain catheter patency allowed~* No concurrent routine chronic systemic corticosteroids~* No concurrent medications that would preclude study compliance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (Gemcitabine Hydrochloride) (Type: ACTIVE_COMPARATOR): Patients receive gemcitabine hydrochloride IV on days 3 and 10.
- Arm II (Gemcitabine Hydrochloride + Imatinib) (Type: EXPERIMENTAL): Patients receive gemcitabine hydrochloride IV on days 3 and 10 and oral imatinib mesylate once daily on days 1-5 and 8-12.

Based on this trial design, predict the completion outcome and termination type (if applicable).